NICE revises its decision on dapagliflozin in triple therapy

NICE has published new guidance recommending the use of dapagliflozin (Forxiga) as an option for treating type II diabetes in adults as part of a triple therapy regimen with metformin and a sulfonylurea.

This supersedes earlier guidance, published in June 2013 (Technology Appraisal Guidance TA288, recommendation 1.3), in which NICE recommended that the use of dapagliflozin as triple therapy with metformin and a sulfonylurea should be confined to clinical trials.

Dapagliflozin is available as Forxiga and as a combined tablet containing both dapagliflozin and metformin (Xigduo).